Guardant Health - GH Stock Forecast, Price & News

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Guardant Health Price Performance

Guardant Health stock traded down $1.87 on Tuesday, reaching $53.17. The company's stock had a trading volume of 745,469 shares, compared to its average volume of 1,265,628. The business's fifty day moving average price is $46.33 and its 200 day moving average price is $54.00. The company has a debt-to-equity ratio of 3.56, a quick ratio of 5.83 and a current ratio of 6.18. The company has a market cap of $5.44 billion, a price-to-earnings ratio of -9.83 and a beta of 0.81. Guardant Health has a twelve month low of $27.65 and a twelve month high of $133.82.

Guardant Health (NASDAQ:GH - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($2.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($1.00). The company had revenue of $109.14 million for the quarter, compared to analyst estimates of $105.14 million. Guardant Health had a negative return on equity of 99.90% and a negative net margin of 135.03%. The firm's quarterly revenue was up 18.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.96) EPS. Equities analysts expect that Guardant Health will post -5.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on GH. Citigroup decreased their price target on Guardant Health from $120.00 to $100.00 in a report on Friday, May 6th. Piper Sandler began coverage on shares of Guardant Health in a research report on Thursday, June 2nd. They set an "overweight" rating and a $65.00 price target on the stock. Morgan Stanley cut their price target on Guardant Health from $85.00 to $80.00 and set an "overweight" rating on the stock in a research note on Monday, August 8th. The Goldman Sachs Group decreased their price target on Guardant Health from $90.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, August 8th. Finally, OTR Global cut shares of Guardant Health to a "positive" rating in a report on Monday, August 1st. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $119.00.

Insider Activity

In other news, SVP Amelia Merrill sold 4,500 shares of the business's stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $53.38, for a total transaction of $240,210.00. Following the completion of the sale, the senior vice president now owns 24,708 shares in the company, valued at $1,318,913.04. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by insiders.